Cargando…

Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study

BACKGROUND: Membranoproliferative glomerulonephritis (MPGN) is an uncommon cause of end stage kidney disease (ESKD) and the clinical outcomes of patients with MPGN who commence kidney replacement therapy have not been comprehensively studied. METHODS: All adult patients with ESKD due to glomerulonep...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Gregory J., Cho, Yeoungjee, Teixiera-Pinto, Armando, Isbel, Nicole, Campbell, Scott, Hawley, Carmel, Johnson, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868684/
https://www.ncbi.nlm.nih.gov/pubmed/31752734
http://dx.doi.org/10.1186/s12882-019-1605-6
_version_ 1783472319871582208
author Wilson, Gregory J.
Cho, Yeoungjee
Teixiera-Pinto, Armando
Isbel, Nicole
Campbell, Scott
Hawley, Carmel
Johnson, David W.
author_facet Wilson, Gregory J.
Cho, Yeoungjee
Teixiera-Pinto, Armando
Isbel, Nicole
Campbell, Scott
Hawley, Carmel
Johnson, David W.
author_sort Wilson, Gregory J.
collection PubMed
description BACKGROUND: Membranoproliferative glomerulonephritis (MPGN) is an uncommon cause of end stage kidney disease (ESKD) and the clinical outcomes of patients with MPGN who commence kidney replacement therapy have not been comprehensively studied. METHODS: All adult patients with ESKD due to glomerulonephritis commencing kidney replacement therapy in Australia and New Zealand from January 1, 1996 to December 31, 2016 were reviewed. Patients with ESKD due to MPGN were compared to patients with other forms of glomerulonephritis. Patient survival on dialysis and following kidney transplantation, kidney recovery on dialysis, time to transplantation, allograft survival, death-censored allograft survival and disease recurrence post-transplant were compared between the two groups using Kaplan Meier survival curves and Cox proportional hazards regression. RESULTS: Of 56,481 patients included, 456 (0.8%) had MPGN and 12,660 (22.4%) had another form of glomerulonephritis. Five-year patient survival on dialysis and following kidney transplantation were similar between patients with ESKD from MPGN and other forms of glomerulonephritis (Dialysis: 59% vs. 62% p = 0.61; Transplant: 93% vs. 93%, p = 0.49). Compared to patients with other forms of glomerulonephritis, patients with MPGN had significantly poorer 5-year allograft survival (70% vs. 81% respectively, p = 0.02) and death censored allograft survival (74% vs. 87%, respectively; p < 0.01). The risk of disease recurrence was significantly higher in patients with MPGN compared to patients with other glomerulonephritidites (18% vs. 5%; p < 0.01). In patients with MPGN who had allograft loss, patients with MPGN recurrence had a significantly shorter time to allograft loss compared to patients with MPGN who had allograft loss due to any other cause (median time to allograft loss 3.2 years vs. 4.4 years, p < 0.01). CONCLUSIONS: Compared with other forms of glomerulonephritis, patients with MPGN experienced comparable rates of survival on dialysis and following kidney transplantation, but significantly higher rates of allograft loss due to disease recurrence.
format Online
Article
Text
id pubmed-6868684
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68686842019-12-12 Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study Wilson, Gregory J. Cho, Yeoungjee Teixiera-Pinto, Armando Isbel, Nicole Campbell, Scott Hawley, Carmel Johnson, David W. BMC Nephrol Research Article BACKGROUND: Membranoproliferative glomerulonephritis (MPGN) is an uncommon cause of end stage kidney disease (ESKD) and the clinical outcomes of patients with MPGN who commence kidney replacement therapy have not been comprehensively studied. METHODS: All adult patients with ESKD due to glomerulonephritis commencing kidney replacement therapy in Australia and New Zealand from January 1, 1996 to December 31, 2016 were reviewed. Patients with ESKD due to MPGN were compared to patients with other forms of glomerulonephritis. Patient survival on dialysis and following kidney transplantation, kidney recovery on dialysis, time to transplantation, allograft survival, death-censored allograft survival and disease recurrence post-transplant were compared between the two groups using Kaplan Meier survival curves and Cox proportional hazards regression. RESULTS: Of 56,481 patients included, 456 (0.8%) had MPGN and 12,660 (22.4%) had another form of glomerulonephritis. Five-year patient survival on dialysis and following kidney transplantation were similar between patients with ESKD from MPGN and other forms of glomerulonephritis (Dialysis: 59% vs. 62% p = 0.61; Transplant: 93% vs. 93%, p = 0.49). Compared to patients with other forms of glomerulonephritis, patients with MPGN had significantly poorer 5-year allograft survival (70% vs. 81% respectively, p = 0.02) and death censored allograft survival (74% vs. 87%, respectively; p < 0.01). The risk of disease recurrence was significantly higher in patients with MPGN compared to patients with other glomerulonephritidites (18% vs. 5%; p < 0.01). In patients with MPGN who had allograft loss, patients with MPGN recurrence had a significantly shorter time to allograft loss compared to patients with MPGN who had allograft loss due to any other cause (median time to allograft loss 3.2 years vs. 4.4 years, p < 0.01). CONCLUSIONS: Compared with other forms of glomerulonephritis, patients with MPGN experienced comparable rates of survival on dialysis and following kidney transplantation, but significantly higher rates of allograft loss due to disease recurrence. BioMed Central 2019-11-21 /pmc/articles/PMC6868684/ /pubmed/31752734 http://dx.doi.org/10.1186/s12882-019-1605-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wilson, Gregory J.
Cho, Yeoungjee
Teixiera-Pinto, Armando
Isbel, Nicole
Campbell, Scott
Hawley, Carmel
Johnson, David W.
Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study
title Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study
title_full Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study
title_fullStr Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study
title_full_unstemmed Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study
title_short Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study
title_sort long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an anzdata registry study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868684/
https://www.ncbi.nlm.nih.gov/pubmed/31752734
http://dx.doi.org/10.1186/s12882-019-1605-6
work_keys_str_mv AT wilsongregoryj longtermoutcomesofpatientswithendstagekidneydiseaseduetomembranoproliferativeglomerulonephritisananzdataregistrystudy
AT choyeoungjee longtermoutcomesofpatientswithendstagekidneydiseaseduetomembranoproliferativeglomerulonephritisananzdataregistrystudy
AT teixierapintoarmando longtermoutcomesofpatientswithendstagekidneydiseaseduetomembranoproliferativeglomerulonephritisananzdataregistrystudy
AT isbelnicole longtermoutcomesofpatientswithendstagekidneydiseaseduetomembranoproliferativeglomerulonephritisananzdataregistrystudy
AT campbellscott longtermoutcomesofpatientswithendstagekidneydiseaseduetomembranoproliferativeglomerulonephritisananzdataregistrystudy
AT hawleycarmel longtermoutcomesofpatientswithendstagekidneydiseaseduetomembranoproliferativeglomerulonephritisananzdataregistrystudy
AT johnsondavidw longtermoutcomesofpatientswithendstagekidneydiseaseduetomembranoproliferativeglomerulonephritisananzdataregistrystudy